会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Oxysalicylamido derivatives
    • 氧代水杨酰胺衍生物
    • US5240957A
    • 1993-08-31
    • US607746
    • 1990-10-29
    • Karl S. BengtssonThomas HogbergLars G. JohanssonTomas DePaulisHans E. P. StromMarianne E. WidmanSven O. gren
    • Karl S. BengtssonThomas HogbergLars G. JohanssonTomas DePaulisHans E. P. StromMarianne E. WidmanSven O. gren
    • C07C65/21C07D207/08
    • C07D207/08C07C65/21
    • Novel therapeutically active compounds of the formula ##STR1## wherein Z.sup.i, being Z.sup.1, Z.sup.2 or Z.sup.3, is the same or different and selected among OH, OR.sup.1, NH.sub.2, NR.sub.2.sup.4, NHR.sup.4, SH, SR.sup.4 and OR.sup.4 wherein R.sup.1 is a formyl group, an acyl group, an alkoxycarbonyl group or a mono- or dialkylcarbamoyl group and R.sup.4 is a lower alkyl group,R.sup.2 is a hydrogen, a halogen, a lower alkyl or a lower trifluoroalkyl group,R.sup.3 is a hydrogen atom, a lower alkyl group, an alkenyl group, an alkynyl group or a phenyl group, which phenyl group could optionally be substituted by one or more of fluoro, chloro, bromo, trifluoromethyl, methyl, ethyl, methoxy or ethoxy in the ortho, meta or para positions, or optionally substituted by methylenedioxy, provided that at least one of Z.sup.1, Z.sup.2 and Z.sup.3 is a group OR.sup.4 and further provided that when Z.sup.2 is OH or NH.sub.2, Z.sup.1 is NR.sub.2.sup.4, NHR.sup.4, SH, SR.sup.4 or OR.sup.4 or a physiologically acceptable salt or optical isomer thereof, intermediates and methods for their preparation, pharmaceutical preparations containing the compounds and methods for their therapeutical use.
    • 其中Z 1,Z 1,Z 2或Z 3相同或不同并且选自OH,OR 1,NH 2,NR 24,NHR 4,SH,SR 4和OR 4中的新颖的治疗活性化合物,其中R 1是甲酰基 ,酰基,烷氧基羰基或单烷基氨基甲酰基,R4为低级烷基,R2为氢,卤素,低级烷基或低级三氟烷基,R3为氢原子,低级烷基 ,链烯基,炔基或苯基,该苯基可以任选被邻位,间位或对位中的一个或多个氟,氯,溴,三氟甲基,甲基,乙基,甲氧基或乙氧基取代,或 任选地被亚甲二氧基取代,条件是Z 1,Z 2和Z 3中的至少一个是OR 4基团,并且进一步规定当Z 2是OH或NH 2时,Z 1是NR 24,NHR 4,SH,SR 4或OR 4或生理上可接受的盐或旋光异构体 中间体及其制备方法,药物制剂c 保持其治疗用途的化合物和方法。